Vol 88, No 9 (2017)
Review paper
Published online: 2017-09-29
Perspectives for the pharmacological treatment of overactive bladder syndrome
Abstract
It has been found that antimuscarinic drugs, viewed as the “gold standard” in overactive bladder syndrome (OAB) treatment, have an unsatisfactory tolerance profile and limited clinical effectiveness. This fact has given a clear impetus to search for new options in OAB pharmacotherapy. The conducted pre-clinical trials have led to the development of new solutions for the treatment of OAB, which stand a good chance of being applied in clinical practice. The said compounds are characterised by higher receptor and organ specificity than currently used medications.
Keywords: overactive bladder syndromepharmacotherapydetrusor overactivity
References
- Leone Roberti Maggiore U, Scala C, Venturini PL, et al. Imidafenacin for the treatment of overactive bladder. Expert Opin Pharmacother. 2013; 14(10): 1383–1397.
- Song M, Kim JH, Lee KS, et al. The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double-blind, placebo-controlled phase 2 study. Int J Clin Pract. 2015; 69(2): 242–250.
- Dmochowski RR, Staskin DR, Duchin K, et al. Clinical safety, tolerability and efficacy of combination tolterodine/pilocarpine in patients with overactive bladder. Int J Clin Pract. 2014; 68(8): 986–994.
- Ohlstein EH, von Keitz A, Michel MC. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol. 2012; 62(5): 834–840.
- Janicki JJ, Chancellor MB, Kaufman J, et al. Potential Effect of Liposomes and Liposome-Encapsulated Botulinum Toxin and Tacrolimus in the Treatment of Bladder Dysfunction. Toxins (Basel). 2016; 8(3).
- Di Rezze S, Frasca V, Inghilleri M, et al. Duloxetine for the treatment of overactive bladder syndrome in multiple sclerosis: a pilot study. Clin Neuropharmacol. 2012; 35(5): 231–234.
- Carbone A, Palleschi G, Conte A, et al. Gabapentin treatment of neurogenic overactive bladder. Pharmacol Exp Therap. 2014; 350: 543–551.
- Lecci A, Maggi CA. Tachykinins as modulators of the micturition reflex in the central and peripheral nervous system. Regul Pept. 2001; 101(1-3): 1–18.
- Merrill L, Vizzard MA. Intravesical TRPV4 blockade reduces repeated variate stress-induced bladder dysfunction by increasing bladder capacity and decreasing voiding frequency in male rats. Am J Physiol Regul Integr Comp Physiol. 2014; 307(4): R471–R480.
- Tyagi V, Philips BJ, Su R, et al. Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium. J Urol. 2009; 181(4): 1932–1938.
- Wróbel A, Rechberger T. The Influence of Maxacalcitol, Vitamin D3 Analog, on Detrusor Overactivity in Conscious Rats. Urology. 2016; 93: 224.e7–224.e15.
- Lecci A, Giuliani S, Meini S, et al. Nociceptin and the micturition reflex. Peptides. 2000; 21(7): 1007–1021.
- Rechberger T, Nowakowski Ł, Rechberger E, et al. Prevalence of common comorbidities among urogynaecological patients. Ginekol Pol. 2016; 87(5): 342–346.
